Resolves YES if the initial U.S. wholesale acquisition cost (WAC) at launch for RP1 (vusolimogene oderparepvec) + nivolumab is ≥ $5,000/course, using the first publicly available WAC from a sponsor price announcement or a pricing compendium (e.g., Red Book / Medi-Span). If RP1 (vusolimogene oderparepvec) + nivolumab does not have an FDA approval for Advanced melanoma (post anti–PD-1 regimen; as described by sponsor) on or before 2026-05-10, resolves NO. Reference: https://www.globenewswire.com/news-release/2025/10/20/3169221/0/en/Replimune-Announces-FDA-Acceptance-of-BLA-Resubmission-of-RP1-for-the-Treatment-of-Advanced-Melanoma.html